Phase 2 N=50 Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Multiple Myeloma
Primary: Objective Response Rate — 6; 16; 11; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=146 A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Neurofibromatosis Type 1
Primary: Paired Associate Learning (Cambridge Neuropsychological Test Automated Battery). — 15.8; 17.0; 10.3; 11.7 PAL Total Errors — p=0.51
Phase 2 N=168 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
Phase 2 N=413 A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
Clostridium Difficile · Clostridium Infections
Primary: Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up. — 2; 7 Participants — p=0.045
Phase 2 N=22 Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy
Alcohol Drinking
Primary: Number of Drinks Consumed During an Ad-libitum Drinking Period — 1.59; 1.64 drinks
Phase 2 N=50 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
Estrogen Receptor-negative Breast Cancer · Estrogen Receptor-positive Breast Cancer · HER2-positive Breast Cancer
Primary: Combined Rate of Microscopic pCR and Macroscopic Pathologic Complete Response (mCR) — 29 Participants
Phase 2 N=42 Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Trough FEV1 (Change From Baseline) — -0.093; 0.0114; 0.0447; 0.0542 liters — p=0.1257
Phase 2 N=10 Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
Relapsed/Refractory Aggressive B-cell Lymphomas
Primary: Maximum Tolerated Dose (MTD) of MEDI-551 — NA; NA mg/kg
Phase 2 N=6 A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumors
Primary: Estimated Steady-State Maximum Plasma Concentration (Cmax,ss) of Sunitinib and Its Metabolite — 37.98; 14.55 nanograms per milliliter (ng/mL)
Phase 2 N=187 A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 47.5; 46.2; 43.6 Percentage of participants — p=0.5543
Phase 2 N=28 Tecemotide (L-BLP25) in Prostate Cancer
Prostate Cancer
Primary: Number of Subjects With Change From Baseline in the Mucinous Glycoprotein 1 (MUC1) Specific Systemic T-Cells Immune Response at Day 60 (Pre-Radiation) — 2; 3 Participants
Phase 2 N=8 Phlebotomy Study of Testosterone Undecanoate
Hypogonadism
Primary: % of Mean Difference in T Concentration Compared to Plain Collection Tube — 8.6; 16.6; 23.2 Difference as % of Mean of T results
Phase 2 N=282 A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
COPD
Primary: Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.0009; 0.1055; 0.1333; 0.1336 liters — p=0.0043
Phase 2 N=119 Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
B-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Inotuzumab Ozogamicin in Combination With Rituximab (375 mg/m^2 ) — 1.8 mg/m^2
Phase 2 N=42 The Fibrin Pad Cardiovascular Study
Cardiovascular Disease
Primary: Hemostasis at the Target Bleeding Site (TBS) at 3 Minutes Following Treatment Application. — 12; 6; 5 Participants